CoChat

Impact Sibutramine Therapy in Children with Hypothalamic Obesity or Obesity with Aggravating Syndromes

Danielsson, Pernilla, Janson, Annika, Norgren, Svante, Marcus, Claude · 2007 · The Journal of Clinical Endocrinology & Metabolism
Cited by 63

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Behavioral treatment of children suffering from hypothalamic obesity or uncomplicated obesity in combination with syndromes that aggravate this condition has proven to be ineffective. The combination of comorbidities and severe obesity lower the quality of these children's lives drastically. The present goal was to determine whether treatment with sibutramine has a beneficial effect on such children. DESIGN AND SUBJECTS: A double-blind, placebo-controlled, cross-over study (20 + 20 wk), followed by a 6-month open phase, was performed. The primary indicator of efficacy was the body mass index (BMI) sd score (SDS) value, which was analyzed using an ANOVA repeated-measures design [intention to treat (ITT)]. The 50 children (7-20 yr of age) involved included 22 with hypothalamic obesity and 28 with uncomplicated obesity plus aggravating syndromes. Forty-five patients completed the first phase, and 42 participated in the entire study. RESULTS: The group that initially received the placebo demonstrated an insignificant decrease (-0.06) in BMI SDS during this treatment but a significant decrease (-0.68; P < 0.001) when treated with sibutramine. The other group demonstrated a reduction in their BMI SDS of -0.72 during administration of sibutramine and a rebound of +0.43 when placed on the placebo (P < 0.001 in both cases). The response of children with hypothalamic obesity was also significant but was less pronounced than that of children with nonhypothalamic obesity. During the open phase, a continuous reduction in weight was observed. The treatment was tolerated well. CONCLUSION: The clinically and statistically significant weight reduction caused by sibutramine in this short-term study indicates that treatment of hypothalamic and syndromal obesity with this drug may be beneficial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2007-0826

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 3 references

Research works printed but not linked: 22

  1. Weiss, 2004, Obesity and the metabolic syndrome in children and adolescents., N Engl J Med, 350, 2362, 10.1056/NEJMoa031049 · DOI · Paper page
  2. Dietz, 2005, Clinical practice. Overweight children and adolescents., N Engl J Med, 352, 2100, 10.1056/NEJMcp043052 · DOI · Paper page
  3. Lindgren, 2000, Eating behavior in Prader-Willi syndrome, normal weight, and obese control groups., J Pediatr, 137, 50, 10.1067/mpd.2000.106563 · DOI
  4. Sorva, 1988, Children with craniopharyngioma. Early growth failure and rapid postoperative weight gain., Acta Paediatr Scand, 77, 587, 10.1111/j.1651-2227.1988.tb10705.x · DOI · Paper page
  5. Geffner, 2004, Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy: analysis of KIGS (Pfizer International Growth Database)., J Clin Endocrinol Metab, 89, 5435, 10.1210/jc.2004-0667 · DOI · Paper page
  6. Farooqi, 2005, Monogenic obesity in humans., Annu Rev Med, 56, 443, 10.1146/annurev.med.56.062904.144924 · DOI · Paper page
  7. Bray, 1984, Syndromes of hypothalamic obesity in man., Pediatr Ann, 13, 525
  8. Muller, 2005, Longitudinal study on quality of life in 102 survivors of childhood craniopharyngioma., Childs Nerv Syst, 21, 975, 10.1007/s00381-004-1124-y · DOI
  9. Poretti, 2004, Outcome of craniopharyngioma in children: long-term complications and quality of life., Dev Med Child Neurol, 46, 220, 10.1111/j.1469-8749.2004.tb00476.x · DOI · Paper page
  10. Ryan, 1995, Sibutramine: a novel new agent for obesity treatment, Obes Res, 3, 553S, 10.1002/j.1550-8528.1995.tb00227.x · DOI · Paper page
  11. Berkowitz, 2003, Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial., JAMA, 289, 1805, 10.1001/jama.289.14.1805 · DOI · Paper page
  12. Godoy-Matos, 2005, Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study., J Clin Endocrinol Metab, 90, 1460, 10.1210/jc.2004-0263 · DOI · Paper page
  13. Berkowitz, 2006, Effects of sibutramine treatment in obese adolescents: a randomized trial., Ann Intern Med, 145, 81, 10.7326/0003-4819-145-2-200607180-00005 · DOI · Paper page
  14. Daniels, 2007, Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study, Pediatrics, 120, e147, 10.1542/peds.2006-2137 · DOI · Paper page
  15. Garcia-Morales, 2006, Use of sibutramine in obese Mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial., Clin Ther, 28, 770, 10.1016/j.clinthera.2006.05.008 · DOI
  16. Van Mil, 2007, The effect of sibutramine on energy expenditure and body composition in obese adolescents., J Clin Endocrinol Metab, 92, 1409, 10.1210/jc.2006-0264 · DOI
  17. Rolland-Cachera, 1982, Adiposity indices in children., Am J Clin Nutr, 36, 178, 10.1093/ajcn/36.1.178 · DOI · Paper page
  18. Cole, 2000, Establishing a standard definition for child overweight and obesity worldwide: international survey., BMJ, 320, 1240, 10.1136/bmj.320.7244.1240 · DOI · Paper page
  19. Yanovski, 2002, Obesity., N Engl J Med, 346, 591, 10.1056/NEJMra012586 · DOI · Paper page
  20. Jeanrenaud, 1985, An hypothesis on the etiology of obesity: dysfunction of the central nervous system as a primary cause., Diabetologia, 28, 502, 10.1007/BF00281984 · DOI
  21. Lustig, 2003, Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial., J Clin Endocrinol Metab, 88, 2586, 10.1210/jc.2002-030003 · DOI · Paper page
  22. Lustig, 1999, Hypothalamic obesity caused by cranial insult in children: altered glucose and insulin dynamics and reversal by a somatostatin agonist., J Pediatr, 135, 162, 10.1016/S0022-3476(99)70017-X · DOI · Paper page

Cited by

See all 63

Metadata

Authors
Danielsson, P., Janson, A., Norgren, S., & Marcus, C.
Affiliations
Department of Paediatrics, Clintec, and the National Childhood Obesity Centre, Karolinska Institutet, Karolinska University Hospital, S-141 86 Stockholm, Sweden
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2007-11-01
Volume
92
Issue
11
Pages
4101-4106
ISSN
  • 0021-972X
  • 1945-7197
Cited by
63
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact Sibutramine Therapy in Children with Hypothalamic Obesity or Obesity with Aggravating Syndromes. https://app.cochat.ai/papers/10.1210/jc.2007-0826
The paper
Danielsson, P., Janson, A., Norgren, S., & Marcus, C. (2007). Impact Sibutramine Therapy in Children with Hypothalamic Obesity or Obesity with Aggravating Syndromes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2007-0826

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.